On April 27 (today), Sun Pharmaceutical Industries Limited (together with its subsidiaries and associates, collectively referred to as “Sun Pharma” hereinafter) and Organon & Co. (“Organon” hereinafter) jointly announced the signing of a definitive acquisition agreement. Under the terms of the agreement, Sun Pharma will acquire all outstanding shares of Organon in an all-cash transaction at a price of $14.00 per share, valuing the target company at $11.75 billion.

As a global healthcare enterprise, Organon was spun off from Merck & Co. as an independent company in 2021.
As a global leader in women’s health, Organon boasts solid brand credibility and strong brand assets. It offers over 70 products spanning two core segments: women’s health and general medicines, with business presence across 140 countries and a robust global footprint supported by six manufacturing sites. Upholding its founding mission in core operations, the company strives to improve access to medicines and reduce treatment costs for people worldwide.
As early as January this year, media reports revealed that Sun Pharma, India’s largest pharmaceutical firm, was evaluating a potential acquisition of U.S.-based pharmaceutical company Organon. In less than half a year, this deal — the largest cross-border acquisition in the history of India’s pharmaceutical industry — has been officially finalized.

With this deal, Sun Pharma now occupies five spots among the top ten M&A transactions in Indian pharmaceutical history, firmly establishing itself as the undisputed representative of India’s pharmaceutical sector. What lessons can this landmark cross border acquisition — the largest ever by an Indian company, valued at over USD 10 billion — offer to China’s industry players?
Following the merger, the two parties will build stronger market competitiveness in the field of .established branded medicines and branded generics The acquisition will also mark Sun Pharma’s official entry into the biosimilar segment, catapulting it into the world’s top ten pharmaceutical rankings. Organon’s rich product pipeline, global business footprint and solid multi party partnerships will highly complement Sun Pharma’s existing strengths, empowering the group to enhance its long term value creation capacity.

Upon successful completion of the transaction, Sun Pharma will secure a brand-new industry positioning:
· Combined annual revenue will reach USD 12.4 billion, ranking it among the world’s top 25 pharmaceutical companies;
· It will emerge as a leading powerhouse in established branded medicines and branded generics;
· The revenue contribution of innovative medicines will rise to 27%, enabling more focused R&D strategies;
· It will secure a top three global position in women’s health and build a sustainable commercial growth platform;
· It will become the world’s seventh largest biosimilar manufacturer;
· Its business will cover 150 countries, with 18 key core markets each generating over USD 100 million in annual revenue.
Cash generation capacity will be significantly enhanced, with EBITDA and operating cash flow expected to nearly double. Post transaction, the net debt to EBITDA ratio will stand at 2.3 times, creating solid conditions for deleveraging.
The transaction has been unanimously approved by the boards of both Sun Pharma and Organon. Final closing remains subject to standard customary conditions, including necessary regulatory clearances and approval by Organon’s shareholders.

▎Core Transaction Highlights
Sun Pharma will acquire all issued and outstanding shares of Organon through a full cash buyout. The purchase consideration will be funded by Sun Pharma using a combination of its available internal cash and committed bank financing. The transaction will be structured as a merger:
· Organon will merge with a subsidiary of Sun Pharma and continue operations as the surviving entity.
· The transaction is expected to close in early 2027, subject to customary closing conditions, including regulatory approvals and approval by Organon’s shareholders.
Key Financials of Organon：
· For the fiscal year ended December 31, 2025, Organon posted annual revenue of US$6.2 billion and adjusted EBITDA of US$1.9 billion; it reported total debt of US$8.6 billion and cash reserves of US$574 million.
· The company recently completed a product asset divestiture and received a US$440 million upfront payment. The net proceeds from this deal will further boost its cash balance in the financial statements ending March 31, 2026.

▎Executive Statements：
Dilip Shanghvi, Executive Chairman of Sun Pharma:“This acquisition represents a major opportunity for Sun Pharma to advance our vision of delivering care for all and safeguarding lives. Organon’s product portfolio, core technologies and global business network are highly complementary to our strengths. We believe the combination will create a stronger, more diversified platform for growth. We fully recognize Organon’s mission and legacy, and will build on its solid foundation to drive long-term and sustainable development.”
Kirti Ganorkar, Managing Director of Sun Pharma:“This transaction is a critical and logical step for Sun Pharma to deepen our global footprint. Post-completion, we will emerge as a preferred global partner for new drug licensing, M&A and commercialization. We will prioritize business continuity, pursue meticulous integration, and steadily deliver social and corporate value. Organon has a high-caliber talent team with great potential, and the combination will unlock substantial synergies, driving meaningful revenue growth in the years ahead.”
Carrie Cox, Executive Chair of Organon:“Following a comprehensive and rigorous review of strategic alternatives, our Board of Directors has concluded that this all-cash transaction delivers immediate and substantial value to Organon’s shareholders. We are confident that Sun Pharma has the full capacity to support Organon’s global operations, employee development and patient care, sustain our corporate vision, and continue providing high-quality medicines and healthcare solutions worldwide.”